The EMBO Journal 'Under Review': What Each Status Means

The EMBO Journal operates the EMBO senior editor + editorial advisory board model with transparent peer review. The senior handling editor reads the entire paper and evaluates molecular biology mechanism, broad significance, and EMBO Journal subspecialty routing.

A senior editor at EMBO Journal typically handles 60 to 100 manuscripts per year and spends 30 to 90 minutes on the initial read; EMBO Journal senior editors are professional editors at EMBO Press supplemented by the editorial advisory board (EAB) for additional consultation on ambiguous-fit papers. The associate editor pool at EMBO supports the senior editors with subspecialty expertise consultation when needed.

EMBO Journal editorial culture is decisive: 74 percent of manuscripts are rejected before formal peer review (21 percent of these with EAB advice). Papers that pass the EMBO senior editor + EAB desk screen have cleared the steepest filter in EMBO molecular biology publishing.

Before the paper reaches external reviewers, an EMBO Journal senior editor evaluates whether the molecular biology mechanism warrants EMBO Journal's selective editorial slots. About 74 percent of submissions are rejected before formal peer review at this stage within 1 week. About 21 percent of these pre-review rejections receive additional advice from the editorial advisory board.

A desk rejection most often means the senior editor (with EAB advice for ambiguous papers) concluded that the work would fit better at a sister EMBO Press journal (EMBO Reports for shorter-format reports, EMBO Molecular Medicine for clinical-translation, Life Science Alliance for open-access multidisciplinary) or that the molecular biology mechanism priority bar is not met.

The EMBO Press editorial office confirms files are complete: manuscript with figures embedded, Supporting Information with molecular biology characterization data, EMBO template formatting, cover letter directed to the senior editor naming molecular biology mechanism contribution, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, and data-availability statement.

The senior editor reads the paper and evaluates molecular biology mechanism, broad significance, and EMBO Journal subspecialty routing. EMBO Press's 1-week editorial decision target reflects rapid editorial response.

In parallel with the senior editor's primary read, ambiguous-fit papers are discussed with the editorial advisory board where peer EAB members weigh in on whether the paper would fit better at EMBO Journal flagship or at sister EMBO Press journals. About 21 percent of pre-review rejections involve EAB advice. This EAB consultation runs alongside the desk-screen and adds 3 to 7 days to the timeline that is invisible to the author in the portal.

EMBO Journal senior editors typically invite 2 to 3 external reviewers under the transparent peer-review model. Reviewer recruitment typically takes 7 to 14 days. The transparent peer-review model means reviewer reports and editorial correspondence become public alongside accepted papers, which can extend recruitment as reviewers consider the public nature of their reports.

Once reviewers agree to review, the typical EMBO Journal peer-review cycle lasts 3 to 5 weeks per reviewer per EMBO Press target. Reviewers are asked to evaluate molecular biology mechanism, broad significance, and reproducibility. Reviewer reports for EMBO Journal tend to be thorough; 2000 to 4000 word reports are typical given the transparent peer-review nature (knowing reports will be published).

After reports return, the senior editor synthesizes them. EMBO Journal allows only 1 round of major revision (which takes ~74 days on average); the journal accepts 95 to 97 percent of invited revisions, 90 to 92 percent after a single round of experimental revision.

• Rejection within 1 to 3 days: Administrative issue or immediate scope mismatch.

• Rejection within 3 to 14 days: Senior editor desk rejection (with EAB advice for ~21% of cases) per the 74 percent figure.

• Still Under Review after 2 weeks: Strong signal. Paper passed the EMBO senior editor + EAB desk screen.

• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. A polite inquiry via the EMBO Press portal is appropriate.

• Status changes to "Decision Pending": Reports are in; expect a decision within 1 week.

This is the most common anxiety we hear from EMBO Journal authors during the active editorial window. The honest answer: no, 5 weeks at Under Review puts you in the normal middle of EMBO Journal's 6 to 8 week median full peer-review distribution. Reports may already be in editorial synthesis with the senior editor preparing the recommendation.

Most reviewer-driven delays come from the transparent peer-review recruitment difficulty (reviewers consider public nature of their reports) rather than slow reviews. If the portal still says Under Review at the 8-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the senior editor granted it. This is normal practice at EMBO Journal.

What you should NOT do during the 5-to-8-week window is email the editorial office. EMBO Journal senior editors are managing 60+ active papers per year; an inquiry at 5 weeks adds friction without accelerating the timeline.

• Do not email the editorial office during the first 4 weeks unless an urgent ethics issue surfaces.

• Do not submit the paper anywhere else while it is Under Review at EMBO Journal. EMBO Press has explicit prohibitions on dual submission.

• Prepare a point-by-point response template for likely reviewer concerns: molecular biology mechanism, broad significance, methodology rigor, reproducibility. Anticipate that reviewer reports will be public under transparent peer review.

• Anticipate the single-round-major-revision policy at EMBO Journal: the first revision is your only chance to address all major reviewer concerns comprehensively.

• Read recent EMBO Journal papers in your subfield to calibrate the current editorial bar.

If your EMBO Journal paper is rejected after review, the natural cascade depends on what the reviewers and senior editor cited:

EMBO Reports is the natural EMBO Press shorter-format cascade. EMBO Press supports manuscript-transfer with reviewer reports preserved (via the EMBO Press multi-journal submission process).

EMBO Molecular Medicine is the EMBO Press cascade for clinical-translation molecular biology papers.

Life Science Alliance is the EMBO/Rockefeller/CSHL open-access cascade for multidisciplinary molecular biology.

Molecular Cell is the external Cell Press cascade for mechanism-depth molecular biology. Molecular Cell uses Editorial Manager at Editorial Manager submission portal; editorial contact molecular-cell@cell.com.

Nature Communications is the external Springer Nature cascade for broader-scope molecular biology. The Nature Communications Manuscript Tracking System at mts-ncomms.nature.com handles submission; ncomms@nature.com handles publisher-level inquiries.

eLife is a cascade option for molecular biology work where the Reviewed Preprint model fits.

EMBO Press asks reviewers at EMBO Journal to evaluate four things specifically. The table below maps each to actionable preparation.

Across EMBO Journal manuscripts, we have reviewed 50+ manuscripts targeting EMBO Journal, EMBO Reports, Molecular Cell, Journal of Cell Biology, Nature Communications, eLife, and related molecular and cell biology journals. In our pre-submission review work across molecular and cell biology venues, the most important reviewed-path separator was whether the manuscript closed the mechanism loop before asking reviewers to trust the story. EMBO Journal is especially unforgiving when the central mechanism is interesting but the experimental logic still reads as one-directional.

EMBO Journal mechanism loop left open in the figures. In our pre-submission review work we see manuscripts with strong perturbation data but no rescue, no gain-of-function complement, weak orthogonal validation, or a model figure that overstates causal certainty. This can survive the initial status stage because the topic is plausible, but reviewers then focus on whether the data prove mechanism or merely association. Stronger submissions make the causal chain visible across the figures, not only in the discussion.

Check whether your EMBO Journal mechanism loop is visible →

EMBO Journal one-round revision plan not credible. A second pattern is a manuscript where the likely reviewer requests are obvious before submission: a rescue experiment, an additional control, a broader cell model, source-data cleanup, or stronger quantification. Because EMBO Journal revisions are expected to resolve major concerns efficiently, entering review with predictable gaps can turn a promising decision into a high-risk revision. Stronger submissions pre-build the response architecture before reviewer reports arrive.

Check if your EMBO Journal revision plan is reviewer-ready →

EMBO Press cascade signal missed after rejection. A third pattern is a paper that has real molecular biology value but belongs better at EMBO Reports, EMBO Molecular Medicine, Life Science Alliance, Molecular Cell, or Journal of Cell Biology depending on mechanism depth, clinical translation, and audience. Authors lose time when they appeal a priority decision that is really a routing decision.

Source limitation: our observations come from Manusights pre-submission and revision-support work, not from private EMBO Press editorial records. We do not train on private author files, and Manusights offers a 60-day money-back guarantee for eligible review orders when the service does not meet the stated scope.

Check your EMBO Journal cascade response plan →

This page was created from EMBO Press's public EMBO Journal author guide at Embopress author instructions, EMBO Press transparent process documentation (1-week editorial decisions, 1-month peer review target, 6 to 8 week median full peer review, 74 percent pre-review desk rejection rate with 21 percent of these receiving EAB advice, 95 to 97 percent acceptance of invited revisions, ~74 day average single round of experimental revision), and Manusights pre-submission review experience with EMBO Journal-targeted manuscripts.

For the EMBO Press molecular biology landscape beyond EMBO Journal, see EMBO Reports (shorter-format), EMBO Molecular Medicine (clinical-translation), Life Science Alliance (open-access multidisciplinary), and external molecular biology alternatives (Molecular Cell, Nature Communications, eLife, JCB). The choice across these titles depends on whether the central contribution is top molecular biology mechanism (EMBO Journal), shorter-format molecular biology (EMBO Reports), clinical-translation molecular biology (EMBO Molecular Medicine), open-access (Life Science Alliance), mechanism-depth (Molecular Cell), broader Nature Portfolio (Nature Communications), Reviewed Preprint (eLife), or cell biology specialty (JCB).

Reviewers at EMBO Journal typically draw from 2 to 3 molecular biology subspecialty experts under a transparent peer-review model. Editors screen and triage manuscripts before any reviewer sees them, and preparing a comprehensive revision response template that addresses every reviewer concern is essential given EMBO Journal's single-round major-revision policy.

For a pre-upload check of your manuscript against the EMBO Journal molecular-biology-mechanism-plus-broad-significance bar before submission, our EMBO Journal pre-submission diagnostic flags the framing and methodology weaknesses most likely to surface in transparent peer review.